The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10B | Blood glucose lowering drugs, excl. insulins | |
4
|
A10BB | Sulfonamides, urea derivatives | |
5
|
A10BB09 | Gliclazide |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 60 mg |
| Active Ingredient |
|---|
|
Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. |
| Document | Type | Information Source | |
|---|---|---|---|
| DIABREZIDE Tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| DIAMICRON MR Modified release tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| GLIZOREM Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| LAMZARIN Prolonged-release tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| MEDOCLAZIDE Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.